Anavex Life Sciences Corp (NASDAQ:AVXL)
| 5.81 Delayed Data As of Jan 15 |  -0.11 / -1.86%Today’s Change | 2.20 Today|||52-Week Range 7.69 | +7.59% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $389.7M |
Company Description
Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.
Contact Information
Anavex Life Sciences Corp. 51 West 52nd Street New York New York 10019-6163 |
Employees
Shareholders
| Other institutional | 8.24% |
| Individual stakeholders | 3.84% |
| Mutual fund holders | 10.96% |
Top Executives
| Christopher U. Missling | Chairman, President, CEO & Secretary |
| Stephan Toutain | Chief Operating Officer |
| Sandra Boenisch | Principal Financial Officer & Treasurer |
| Walter E. Kaufmann | Chief Medical Officer |
| Daniel Klamer | VP-Business Development & Scientific Strategy |
